NCT05660421View on ClinicalTrials.gov

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

April 30, 2027

Conditions
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Interventions
DRUG

Itacitinib

Given by mouth

DRUG

Corticosteroid

Given by mouth or by vein

PROCEDURE

Endoscopic Procedure

Undergo endoscopic procedure

PROCEDURE

Skin biopsy

Undergo skin biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood and stool

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Douglas Johnson

OTHER

NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter